Compare FG & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FG | TMDX |
|---|---|---|
| Founded | 1959 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.9B |
| IPO Year | N/A | 2019 |
| Metric | FG | TMDX |
|---|---|---|
| Price | $31.37 | $126.71 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $41.00 | ★ $144.25 |
| AVG Volume (30 Days) | 262.2K | ★ 791.4K |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | ★ 3.20% | N/A |
| EPS Growth | ★ 3428.12 | 170.70 |
| EPS | ★ 3.42 | 2.54 |
| Revenue | ★ $5,559,000,000.00 | $566,354,000.00 |
| Revenue This Year | N/A | $38.81 |
| Revenue Next Year | $13.46 | $20.49 |
| P/E Ratio | ★ $9.12 | $50.55 |
| Revenue Growth | N/A | ★ 41.20 |
| 52 Week Low | $28.70 | $55.00 |
| 52 Week High | $47.76 | $156.00 |
| Indicator | FG | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 47.35 |
| Support Level | $30.45 | $120.82 |
| Resistance Level | $35.33 | $133.29 |
| Average True Range (ATR) | 1.13 | 5.70 |
| MACD | -0.39 | -0.88 |
| Stochastic Oscillator | 23.57 | 32.54 |
F&G Annuities & Life Inc is a provider of insurance solutions serving retail annuity and life customers as well as institutional clients. Through its insurance subsidiaries, including FGL Insurance and Fidelity & Guaranty Life Insurance Company of New York it markets a broad portfolio of deferred annuities (fixed indexed annuities (FIAs) and multi-year guarantee annuities (MYGAs) or other fixed rate annuities), immediate annuities, indexed universal life (IUL) insurance, funding agreements through funding agreement-backed notes (FABN) issuances and the Federal Home Loan Bank of Atlanta (FHLB)), and pension risk transfer (PRT) solutions.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.